SITE003-0112

SITE003 (CAN) › SITE003-0112

SITE003-0112

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2026-01-18

enrolled

AEs

8

Serious

0

Dropout signal

–

Adverse events

8

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-11-06 (study day 108); relationship: not assessed

moderate assessed

Grade 2 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2022-11-03 (study day 105); relationship: not assessed

moderate assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-10-30 (study day 101); relationship: NOT RELATED

mild assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-19 (study day 90); relationship: not assessed

moderate assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-10-10 (study day 81); relationship: not assessed

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-09-19 (study day 60); relationship: not assessed

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-09-01 (study day 42); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-12 (study day 22); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.